CYTOSORBENTS CORPORATION (NASDAQ:CTSO) Files An 8-K Results of Operations and Financial Condition
Item 2.02
|
Results of Operations and Financial Condition. |
On March 3, 2017, CytoSorbents Corporation (the Company) filed
its Annual Report on Form 10-K reporting its financial results
for the fourth quarter and twelve months ended December 31, 2016.
On that day, the Company also conducted a conference call during
which members of its senior management team discussed the
financial results for the fourth quarter and twelve months ended
December 31, 2016, a business update, and certain other
information. A copy of the transcript of the conference call is
furnished herewith as Exhibit 99.1.
On March 3, 2017, the Company also issued a press release
announcing its financial results for the period ended December
31, 2016. A copy of the press release is furnished herewith as
Exhibit 99.2.*
| Item 9.01 | Financial Statements and Exhibits. |
(d) Exhibits.
| Exhibit No. | Description |
| 99.1 |
Transcript of the CytoSorbents Corporation Conference Call on March 3, 2017, 11:00 am EST. |
| 99.2 | CytoSorbents Corporation Press Release, dated March 3, 2017. |
* The information in Item 2.02 of this Form8-K shall not be
deemed filed for purposes of Section18 of the Securities Exchange
Act of 1934 (the Exchange Act) or otherwise subject to the
liabilities of that section, nor shall it be deemed incorporated
by reference in any filing under the Securities Act of 1933 or
the Exchange Act, except as expressly set forth by specific
reference in such a filing.
About CYTOSORBENTS CORPORATION (NASDAQ:CTSO)
CytoSorbents Corporation is a critical care focused immunotherapy company. The Company is engaged in commercializing its product, CytoSorb, which is a blood purification technology with focus in preventing or treating multiple organ failure. The Company’s purification technologies are based on biocompatible, porous polymer beads that remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. The Company’s CytoSorb is an extracorporeal cytokine filter and is designed to reduce the cytokine storm that causes inflammation, organ failure and death in common critical illnesses, such as sepsis, burn injury, trauma, lung injury and pancreatitis. In addition, CytoSorb is used in other inflammatory conditions, such as cardiac surgery and autoimmune disease flares and cancer cachexia. It also has other products under development based upon its blood purification technology, including HemoDefend, ContrastSorb, DrugSorb, BetaSorb and others. CYTOSORBENTS CORPORATION (NASDAQ:CTSO) Recent Trading Information
CYTOSORBENTS CORPORATION (NASDAQ:CTSO) closed its last trading session down -0.10 at 5.25 with 59,247 shares trading hands.